# Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes

> **NCT03254368** · PHASE2 · COMPLETED · sponsor: **Zafgen, Inc.** · enrollment: 188 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Overweight and Obesity

## Interventions

- **DRUG:** ZGN-1061
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03254368
- **Lead sponsor:** Zafgen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-12
- **Primary completion:** 2018-11-12
- **Final completion:** 2019-02-22
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2019-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254368, "Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03254368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*